EMPLOYMENT AGREEMENTEmployment Agreement • April 9th, 2004 • Celldex Therapeutics Inc • New Jersey
This EMPLOYMENT AGREEMENT (the "Agreement") is entered into this 6th day of April, 2004 (the "Effective Date"), between Anthony S. Marucci (the "Executive") and CELLDEX THERAPEUTICS, INC. (the "Company") (collectively, the Executive and the Company shall be referred to as the "Parties"). In consideration of the mutual promises and agreements contained herein, the Parties agree as follows:
ASSIGNMENT AND LICENSE AGREEMENTAssignment and License Agreement • September 22nd, 2004 • Celldex Therapeutics Inc • Biological products, (no disgnostic substances) • New Jersey
[*****] REPRESENTS CONFIDENTIAL PORTION WHICH HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
RESEARCH AND COMMERCIALIZATION AGREEMENTResearch and Commercialization Agreement • September 22nd, 2004 • Celldex Therapeutics Inc • Biological products, (no disgnostic substances) • New Jersey
This Research and Commercialization Agreement (the “Agreement”), effective as of April 6, 2004 (the “Effective Date”), is entered by and between Medarex, Inc., a New Jersey corporation, with a principal place of business at 707 State Road, Princeton, New Jersey 08540, GenPharm International, Inc., a wholly owned subsidiary of Medarex, Inc., (collectively, “Medarex”), and Celldex Therapeutics, Inc., a Delaware corporation, with a principal place of business at 519 Route 173 W, Bloomsbury, New Jersey 08804 (“Celldex”).
RESEARCH COLLABORATION AND COMMERCIALIZATION AGREEMENTConfidential Treatment • March 2nd, 2009 • Celldex Therapeutics Inc • Biological products, (no disgnostic substances) • New Jersey
THIS RESEARCH AND COMMERCIALIZATION AGREEMENT (the “Agreement”), effective as of October 20, 2006 (the “Effective Date”), is entered by and between CELLDEX THERAPEUTICS, INC., a New Jersey corporation, with a principal place of business at 222 Cameron Drive, Suite 400, Phillipsburg, New Jersey, NJ 08865, (“Celldex”) and the LUDWIG INSTITUTE FOR CANCER RESEARCH, a Swiss not-for-profit corporation with a registered office at Stadelhoferstrasse 22, 8001 Zurich, Switzerland, and an office at 605 Third Avenue, 33rd Floor, New York, NY 10158 USA, (“Ludwig”).
Vaccine Adjuvant License and Collaboration AgreementConfidential Treatment • March 2nd, 2009 • Celldex Therapeutics Inc • Biological products, (no disgnostic substances) • Minnesota
This Agreement is made on the 30th day of May, 2008 (“Effective Date”) by and among 3M COMPANY (“3M”) and 3M INNOVATIVE PROPERTIES COMPANY (“3M IPC”), a wholly-owned subsidiary of 3M, both with a principal address as 3M Center, St. Paul, MN 55144 (collectively “3M”); and Celldex Therapeutics, with a principal address at 222 Cameron Drive Suite 400, Phillipsburg, NJ 08865 (“CELLDEX”).
ContractConfidential Treatment • March 2nd, 2009 • Celldex Therapeutics Inc • Biological products, (no disgnostic substances) • Southampton
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [*], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
LEASE AGREEMENTCelldex Therapeutics Inc • April 9th, 2004 • New Jersey
AFFILIATION AGREEMENTAffiliation Agreement • April 9th, 2004 • Celldex Therapeutics Inc • Delaware
This AFFILIATION AGREEMENT (the "Agreement") is made and entered into as of April 6, 2004, by and between Medarex, Inc., a New Jersey corporation ("Medarex"), and Celldex Therapeutics, Inc., a Delaware corporation and a wholly-owned subsidiary of Medarex as of the date hereof ("Celldex"). Certain capitalized terms used herein are defined in Section 1 of this Agreement (Medarex and Celldex are sometimes hereinafter individually referred to as a "Party" or collectively as the "Parties").
AGREEMENT AND PLAN OF MERGER OF CELLDEX THERAPEUTICS, INC., a New Jersey corporation INTO CELLDEX THERAPEUTICS, INC., a Delaware corporationCelldex Therapeutics Inc • April 9th, 2004
AGREEMENT AND PLAN OF MERGER dated as of April 2, 2004, between Celldex Therapeutics, Inc., a New Jersey corporation ("Celldex NJ"), and Celldex Delaware Therapeutics, Inc., a Delaware corporation ("Celldex Delaware"). Celldex NJ and Celldex Delaware are sometimes referred to herein as the "Constituent Corporations".
AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • June 8th, 2005 • Celldex Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
ASSET PURCHASE AGREEMENT (this “Agreement”), dated as of January 31, 2005 (the “Execution Date”), by and between Celldex Therapeutics, Inc., a Delaware corporation (including its assignees, (the “Acquirer”), and Alteris Therapeutics, Inc., a Delaware corporation (the “Transferor”; and together with the Acquirer, each, a “Party” and, collectively, the “Parties”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 9th, 2004 • Celldex Therapeutics Inc • Delaware
This REGISTRATION RIGHTS AGREEMENT is made and entered into as of April 6, 2004, by and between Medarex, Inc., a New Jersey corporation ("Medarex"), and Celldex Therapeutics, Inc., a Delaware corporation and a wholly owned subsidiary of Medarex (the "Company"). Certain capitalized terms used herein are defined in Section 1 of this Agreement.
CELLDEX THERAPEUTICS, INC. (a Delaware corporation) SHARES OF COMMON STOCK (par value $0.01 per share) PURCHASE AGREEMENTPurchase Agreement • June 8th, 2005 • Celldex Therapeutics Inc • Biological products, (no disgnostic substances) • Pennsylvania
Celldex Therapeutics, Inc., a Delaware corporation (“Celldex” or the “Company”), confirms its agreement with Janney Montgomery Scott LLC, a Pennsylvania corporation (“Janney”) and ThinkEquity Partners LLC, a limited liability company (“ThinkEquity”), and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any Underwriters substituted as hereinafter provided in Section ), for whom Janney and ThinkEquity are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the number of shares of the Company’s class of Common Stock, par value $0.01 per share (the “Common Stock”), set forth in Schedule A hereto (the “Initial Securities”) and (ii) the grant by the Company to the Underwriters of the option described in Section hereof to purchase all or any part of additional shares of Common Stock to
AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • March 29th, 2005 • Celldex Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
ASSET PURCHASE AGREEMENT (this "Agreement"), dated as of January 31, 2005 (the "Execution Date"), by and between Celldex Therapeutics, Inc., a Delaware corporation (including its assignees, (the "Acquirer"), and Alteris Therapeutics, Inc., a Delaware corporation (the "Transferor"; and together with the Acquirer, each, a "Party" and, collectively, the "Parties").
CONFIDENTIALITY AGREEMENTConfidentiality Agreement • April 9th, 2004 • Celldex Therapeutics Inc • New Jersey
This CONFIDENTIALITY AGREEMENT is made and entered into as of April 6, 2004, by and between Medarex, Inc., a New Jersey corporation ("Medarex"), and Celldex Therapeutics, Inc., a Delaware corporation and a wholly owned subsidiary of Medarex ("Celldex").
MASTER SERVICES AGREEMENTMaster Services Agreement • April 9th, 2004 • Celldex Therapeutics Inc • New Jersey
THIS MASTER SERVICES AGREEMENT (this "Agreement") is entered into this 6th day of April, 2004 (the "Effective Date") by and between CELLDEX THERAPEUTICS, INC., a Delaware corporation, with principal offices located at 519 Route 173 W, Bloomsbury, NJ 08804 ("Celldex"), and MEDAREX, INC., a New Jersey corporation, with principal offices located at 707 State Road, Princeton, NJ 08540 ("Medarex").
